9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex Announces $60 Million Private Placement

Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

Athenex, Inc. Announces Third Quarter 2019 Financial Results

Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

Athenex, Inc. to Report Third Quarter 2019 Earnings Results on November 7, 2019

Athenex Provides An Update to Shareholders

Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.